Melanoma is the most lethal skin cancer that originates from the malignant transformation of
melanocytes. Although melanoma has long been regarded as a cancerous malignancy with …

Immune checkpoint therapy (ICT) can provide durable clinical responses and improve
overall survival. However, only subsets of patients with specific tumor types respond to ICT …

Background Whether pembrolizumab given both before surgery (neoadjuvant therapy) and
after surgery (adjuvant therapy), as compared with pembrolizumab given as adjuvant …

Neoadjuvant ipilimumab and nivolumab induces high pathologic response rates (pRRs) in
clinical stage III nodal melanoma, and pathologic response is strongly associated with …

Relatlimab and nivolumab combination immunotherapy improves progression-free survival
over nivolumab monotherapy in patients with unresectable advanced melanoma. We …

The gut microbiota shapes the response to immune checkpoint inhibitors (ICIs) in cancer,
however dietary and geographic influences have not been well-studied in prospective trials …

Exosomes are the phospholipid-membrane-bound subpopulation of extracellular vesicles
derived from the plasma membrane. The main activity of exosomes is cellular …

Immunotherapy has revolutionized cancer treatment and substantially improved patient
outcome with regard to multiple tumour types. However, most patients still do not benefit …

Surgery for locoregionally advanced head and neck squamous cell carcinoma (HNSCC)
results in 30‒50% five-year overall survival. In IMCISION (NCT03003637), a non …

Preoperative immunotherapy with anti-PD1 plus anti-CTLA4 antibodies has shown
remarkable pathological responses in melanoma and colorectal cancer. In NABUCCO …